Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cancer: early-phase trial registry
279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #6 of 28,707 conditions by registered trial count.
621 US clinical trials · 279 currently recruiting · #6 of 28,707 conditions by registered trial count
Cancer: 621 US clinical trials tracked, 279 recruiting.
Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition cancer
OPEN 279 | RECR 45% | LATE 31 | EARLY 164 | RANK #6 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Duchenne Muscular Dystrophy (45% recruiting · 49 trials)
Cancer lists 279 open slots (45% of 621 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cancer is recruiting above its size-band peers.
279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.
-
Typical Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.
-
Cancer research is mostly interventional.
462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
621 total, page 8 of 13
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
University of California, San Francisco
NCT03739372
Assessment of Paclitaxel-Induced Neuropathy
University of Chicago
NCT01953159
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International
NCT05163028
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05704985
Researching the Effect of Aerobic Exercise on Cancer
Memorial Sloan Kettering Cancer Center
NCT03996239
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
Boston Scientific Corporation
NCT06192758
Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices
M.D. Anderson Cancer Center
NCT05124405
Ovarian Reserve Testing in Female Young Adult Cancer Survivors
University of California, San Diego
NCT01421095
Expanding Rural Health Cancer Control Capacity
Debra Friedman
NCT04765072
Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients
Mary Charlton
NCT05645328
ACT-Together (Acting on Cancer Testing-Together)
M.D. Anderson Cancer Center
NCT06549153
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
UNC Lineberger Comprehensive Cancer Center
NCT05823740
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT03943901
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Adam Burgoyne, MD, PhD
NCT03556384
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
St. Jude Children's Research Hospital
NCT05164016
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
University of California, Irvine
NCT06340906
Virtual Exercise Program to Reduce Cancer Related Fatigue
University of Colorado, Denver
NCT04533165
Exercise Rehabilitation in Veteran Cancer Survivors
VA Office of Research and Development
NCT03621813
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
NCT06754501
Development of Computer-aided Detection and Diagnosis From Imaging Techniques
National Institutes of Health Clinical Center (CC)
NCT00057252
Development and Validation of Harbinger Health Test for Early Cancer Detection
Harbinger Health
NCT05435066
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Freenome Holdings
NCT05254834
Cooking for Health Optimization With Patients
Tulane University
NCT03443635
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
National Eye Institute (NEI)
NCT00116090
Epidemiology of Venous Thromboembolism
Brigham and Women's Hospital
NCT00456196
Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center
Northwestern University
NCT03988543
Community Cancer Centers Pilot Patient Survey
National Cancer Institute (NCI)
NCT00786656
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Sanofi
NCT00694382
The Genetic Information and Family Testing (GIFT) Study
University of Michigan Rogel Cancer Center
NCT05552664
Pesticides--Health Fertility and Reproductive Risk
National Institute of Environmental Health Sciences (NIEHS)
NCT00015561
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Novartis Pharmaceuticals
NCT01235962
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine
NCT02620527
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
NCT00082433
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
NCT02073682
Serious Illness Communication Project
Dana-Farber Cancer Institute
NCT01786811
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
Alliance Foundation Trials
NCT02744092
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix
NCT04264767
Genetic Testing in Young Adults With Cancer Study
University of Pennsylvania
NCT04533555
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
NCT00940225
Ezra Faster Scan Study
Ezra AI
NCT05385718
Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
Abramson Cancer Center at Penn Medicine
NCT04738643
Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial
University of Pittsburgh
NCT03824158
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
Kaiser Permanente
NCT04351880
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
University of North Carolina, Chapel Hill
NCT01969370
Promoting Healthy Lifestyles Among Firefighters
Oregon Health and Science University
NCT00006181
Multidisciplinary Inpatient Palliative Care Intervention
Kaiser Permanente
NCT00325611
Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers
University of California, San Diego
NCT02534675
Effective Communication for Preventing and Responding to Oncology Adverse Events
University of Massachusetts, Worcester
NCT01871948
Post-chemotherapy Symptom Management SMART
University of Arizona
NCT03494166
ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making)
Washington University School of Medicine
NCT02929108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 116 |
| Phase 2 | 48 |
| Phase 3 | 27 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cancer page
621 registered trials, 279 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 279 Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer condition card totals 621 registered trials; most-linked intervention Usual Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.